Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.

Borgia, Sergio M

Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. [electronic resource] - Journal of hepatology 10 2019 - 660-665 p. digital

Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

1600-0641

10.1016/j.jhep.2019.05.028 doi


Antiviral Agents--administration & dosage
Carbamates--administration & dosage
Drug Combinations
Drug Monitoring--methods
Female
Hepacivirus--genetics
Hepatitis C, Chronic--complications
Heterocyclic Compounds, 4 or More Rings--administration & dosage
Humans
Kidney Failure, Chronic--complications
Liver Cirrhosis--diagnosis
Male
Middle Aged
Renal Dialysis--methods
Sofosbuvir--administration & dosage
Sustained Virologic Response
Treatment Outcome